Search Health technology assessments

Search health technology assessments, from Assyro's copies of each agency's published register: g-ba (the German Federal Joint Committee's decisions on the added benefit of new medicines under section 35a SGB V, AMNOG: one record per patient group, with G-BA's own added-benefit statement, its extent ("erheblich" major, "beträchtlich" considerable, "gering" minor, "nicht quantifizierbar" non-quantifiable, "ist nicht belegt" not proven, "geringerer Nutzen" lesser) and certainty ("Beleg" proof, "Hinweis" indication, "Anhaltspunkt" hint), the appropriate comparator therapy, decision date and orphan status), iqwig (IQWiG dossier assessments: project number such as A26-86, title naming substance and indication, DOI; IQWiG's conclusion itself is not held). Omit agency to search both. Find by product (trade name), substance (G-BA writes German INNs: "Cabazitaxel", "Fampridin"), indication or patient group words, the added benefit in German or English ("considerable", "not proven"), certainty, the agency's identifier (G-BA procedure number "2011-04-15-D-003", IQWiG project "A26-86"), ATC code, orphan status or decision date. G-BA writes in German: quote its words and give your translation. NICE (UK) and CDA-AMC (Canada) recommendations are NOT held (their terms do not permit copying): say so, never read their absence as a refusal. An agency that is not loaded is reported as not searched: never read that as "not assessed". Call read_hta_assessment for the whole record.